MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15145367

Медицинская библиотека · Journal of clinical medicine · 2026

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Lixi Filippo, Timofte-Zorila Mihaela-Madalina, Tomi Mara-Ioana, Rapisarda Lorenzo, Messina Marco, Lacrinova Experience Working Group

СтатьяПеревод в очереди

Аннотация

Background

Dry Eye Disease (DED) is a multifactorial condition with an impact on quality of life and an often suboptimal response to conventional lubricants. This study aimed at evaluating the real-world efficacy, tolerability, and patient adherence of a therapy with a novel ophthalmic solution containing Ribohyal, a riboflavin-hyaluronic acid complex, used in patients with DED.

Methods

This national survey included data from adult patients with clinically diagnosed DED treated with Lacrinova eye drops (4 times/day for 3 months) whose data were collected from 82 Italian ophthalmologists. Patients were assessed before (T0) and after treatment (T1). Outcomes included patient-reported symptoms for 9 domains (0-10 numerical rating scale), objective clinical parameters (best-corrected visual acuity [BCVA], break-up time [BUT], and corneal fluorescein staining [CFS]), and treatment acceptability.

Results

Data from 2993 patients (5986 eyes) were analyzed. Improvements were observed across all 9 symptom domains, with reductions ranging from 53% to 60% (all p < 0.001). BCVA and BUT significantly improved (from 0.08 ± 0.22 at T0 to 0.06 ± 0.19 logMAR at T1 and from 9.20 ± 4.49 to 11.85 ± 4.66 s at T1, respectively, both p < 0.001). The prevalence of CFS decreased from 42.0% to 23.4% (p < 0.001). Treatment acceptability was high, with mean scores of 8.88± 1.49 for tolerability, 8.55 ± 1.63 for adherence, and 8.62 ± 1.55 for perceived efficacy. No relevant adverse events were reported.

Conclusions

Lacrinova eye drops demonstrated significant improvements in both symptoms and clinical signs of DED, with excellent tolerability and adherence. These findings support its use as an effective therapeutic option in routine clinical practice, although controlled studies are warranted to confirm the efficacy.

Для цитирования: Lixi Filippo, Timofte-Zorila Mihaela-Madalina, Tomi Mara-Ioana, Rapisarda Lorenzo, Messina Marco, Lacrinova Experience Working Group. A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15145367.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.